|
NEWS von heute: Bio-Treat’s New JV Partnership with the Japanese 18 January 2007 – The Board of Directors of Bio-Treat Technology Limited (the “Company”) is pleased to announce that its wholly-owned subsidiary Bio-Treat International Limited (“Bio-Treat”), has entered into an agreement with All Praise Limited (“AP”), a company that represents the Japanese joint-venture partners’ interest, to carry out wastewater treatment related business through a newly established joint venture company High Result Limited (“HR”). AP, a company incorporated in the British Virgin Islands, is the business vehicle that has been adopted by the Japanese joint venture partners for the purpose of entering into the JV Agreement with Bio-Treat. Under the terms of the JV agreement, Bio-Treat will own 60% of HR while AP will own the remaining 40% of HR. Through this joint venture, Bio-Treat will gain access to a unique physical/chemical process technology (the “Japanese Technology”) that was invented by its Japanese joint-venture partners. They had further invented a product, a proprietary blend of coagulant named Aqua-Mate, for wastewater and polluted water treatment utilizing the Japanese Technology. Based on our joint-venture agreement, the ownership rights to both the Japanese Technology and Aqua-Mate will be transferred to HR. Aqua- Mate has been tested to be especially effective and efficient for treating refractory industrial wastewater which is a term used to describe complex or complicated mixes of industrial wastewater. For instance, this proprietary coagulant is able to remove colours, heavy metals, and other toxic components from industrial wastewater. It has also been proven effective for handling other treatment requirements which are difficult for the traditional coagulants to handle. Bio-Treat plans to implement the Japanese Technology on its industrial and municipal wastewater treatment projects for the primary stage or pre-treatment process prior to subjecting the wastewater to the secondary stage of treatment using its own BMS Biological Process Technology. Bio-Treat believes that by applying the unique combination of the Japanese Technology and its proprietary BMS Biological Process Technology for treating wastewater, the output quality of the treated water will be significantly improved, as compared to that which has been treated by the other traditional forms of pre-treatment. With the distinct benefits and competitive advantages arising from the combination of the two technologies, Bio-Treat believes that the joint venture will put the Group in good stead to: • Expand the scope of its business into two new areas - Refractory Industrial Wastewater Treatment and Water Recycling. The Japanese Technology has been tested to be effective for both of these purposes. • Be in an even stronger position than before to bid for large-scale municipal projects, especially those that entail the treatment of a high percentage of industrial wastewater, and those which its competitors are not able to treat, or cannot treat to the required discharge standard of the Environmental Protection Agency in the PRC. • Expand into the Japanese market - Bio-Treat intends to leverage on the joint venture as an entry point for the expansion of its business into the Japanese market. According to the terms of the joint venture agreement, Bio-Treat has the right to export the coagulant produced by HR in its PRC production facilities to the Japanese market. With regard to intellectual property protection, the Japanese joint-venture partners have filed an application in the PRC for the Japanese Technology and for the corresponding proprietary coagulant produced using this technology. This patent application will be transferred to the joint venture vehicle HR. The Company believes that the joint venture will bring positive benefits in the long run for the following reasons:- • New streams of recurring income generated through the new businesses of the joint venture. • Expected increases in volume of industrial wastewater treatment business due to the application of the unique combination of the Japanese Technology with Bio-Treat’s proprietary BMS Biological Process Technology on existing and future projects. • Increased volume of industrial wastewater treatment business translates to higher profit margins for that business as industrial wastewater treatment, as compared to domestic wastewater treatment yields higher profit margins. • With this new Japanese Technology, Bio-Treat has the ability to take on wastewater treatment projects that require a very specialized form of pretreatment due to pollutant complexity, especially in certain types of industrial wastewater. • Expected new project opportunities arising from utilizing the two technologies. For instance, with this joint venture in place, Bio-Treat believes that it will be in a good position to bid for recycling projects in the northern China region where recycling of water is urgently needed. Under the terms of the JV agreement, Bio-Treat will have certain rights including the intellectual property usage rights of the Japanese Technology as described above. The total amount of the Company’s investment in this joint-venture is RMB14.4 million and it will be funded through internal resources. None of the Company’s directors or substantial shareholders has any direct or indirect interest in the joint venture. |
|
| aus der Diskussion: | Erstes chinesisches Unternehmen im NAI (Natur-Aktien-Index) |
| Autor (Datum des Eintrages): | Sugar2000 (18.01.07 10:01:04) |
| Beitrag: | 16 von 26 (ID:27004393) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |